Abstract
Objective To identify strains of Escherichia coli that do not produce Extended Spectrum Betalactamases (ESBL) in urine cultures and to evaluate the patterns of resistance to certain antibiotics used in clinical practice as treatments of choice in the Toluca Valley of Mexico.
Method 155 urine samples were obtained from people in the Toluca Valley, Mexico under necessary hygiene conditions. 100ml used to identify the pathogen and its resistance patterns were collected from each sample, using an automated Walkaway method.
Result 19 strains of non-ESBL-producing Escherichia coli were obtained, of which 68.42% showed resistance to ampicillin and tetracycline, 47.36% resistance to trimethoprim with sulfamethoxazole, 26.31% for levofloxacin, ciprofloxacin, ceftriaxone, and resistance of 21 % with ampicillin and sulbactam. 100% sensitivity for amikacin, tigecycline and carbapenems.
Conclusion Antibiotic resistance represents a major health problem, as the present study shows, ampicillin is a drug of choice for urinary tract infection produced by Eschericha coli, but in the Toluca Valley the resistance to this antibiotic is 68.42% In non-ESBL producing strains, high resistance patterns are also shown for quinolones, tetracycline and trimethoprim with sulfamethoxazole.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors declare that they have no conflict of interest. No funding was received to carry out this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Microtec Laboratories Ethics Committee has indicated that the research project does not need approval.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Readers will be able to access the data here present, citing and giving credit to the authors of this research work.
